BidaskClub lowered shares of Endo International PLC (NASDAQ:ENDP) from a hold rating to a sell rating in a research report sent to investors on Monday.

Several other equities analysts also recently commented on ENDP. Royal Bank Of Canada set a $15.00 price target on shares of Endo International PLC and gave the company a hold rating in a report on Saturday, April 8th. Canaccord Genuity reissued a hold rating and issued a $14.00 price objective on shares of Endo International PLC in a research report on Tuesday, April 11th. Mizuho reissued a buy rating and issued a $18.00 price objective (up from $17.00) on shares of Endo International PLC in a research report on Thursday, April 13th. Vetr cut shares of Endo International PLC from a strong-buy rating to a hold rating and set a $11.34 price objective for the company. in a research report on Thursday, April 27th. Finally, BMO Capital Markets reissued a hold rating and issued a $15.00 price objective on shares of Endo International PLC in a research report on Monday, May 1st. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating and six have assigned a buy rating to the company. Endo International PLC has an average rating of Hold and a consensus target price of $17.33.

Endo International PLC (NASDAQ:ENDP) traded down 5.35% during mid-day trading on Monday, hitting $9.38. 10,510,537 shares of the stock were exchanged. The company’s 50-day moving average price is $11.45 and its 200 day moving average price is $11.76. Endo International PLC has a 52 week low of $9.36 and a 52 week high of $24.93. The firm’s market capitalization is $2.09 billion.

Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings results on Tuesday, May 9th. The company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.10 by $0.13. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The firm’s revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.08 EPS. Equities research analysts expect that Endo International PLC will post $3.54 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/04/bidaskclub-downgrades-endo-international-plc-endp-to-sell.html.

Large investors have recently bought and sold shares of the stock. First Quadrant L P CA purchased a new stake in Endo International PLC during the first quarter worth approximately $24,556,000. OppenheimerFunds Inc. boosted its stake in Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock worth $32,065,000 after buying an additional 1,857,678 shares during the last quarter. Norges Bank purchased a new stake in Endo International PLC during the fourth quarter worth approximately $26,929,000. Bank of New York Mellon Corp boosted its stake in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock worth $25,345,000 after buying an additional 633,904 shares during the last quarter. Finally, Diamond Hill Capital Management Inc. purchased a new stake in Endo International PLC during the second quarter worth approximately $5,454,000. 92.83% of the stock is owned by institutional investors.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.